Preferred Label : Allogeneic Anti-BCMA/CS1 Bispecific CAR-T Cells;
NCIt synonyms : Allogeneic Anti-BCMA/CS1 Bispecific CAR T-cells; Allogeneic BCMA/SLAMF7 Bispecific CAR-T Cells; Allogeneic BCMA/CS1 Bispecific CAR-T Cells; Allogeneic Anti-BCMA/SLAMF7 Bispecific CAR-T Cells;
NCIt definition : A preparation of allogeneic T-lymphocytes that have been genetically modified to express
a chimeric antigen receptor (CAR) targeting both the tumor-associated antigens (TAAs)
B-cell maturation antigen (BCMA; TNFRSF17) and human CS1 (CD2 subset 1; SLAM family
member 7; SLAMF7; CD319; CRACC), with potential immunomodulating and antineoplastic
activities. Upon administration, the allogeneic anti-BCMA/CS1 bispecific CAR-T cells
target and bind to tumor cells expressing BCMA and/or CS1 and induce selective cytotoxicity
in those cells. BCMA, a receptor for both a proliferation-inducing ligand (APRIL)
and B-cell activating factor (BAFF), is a member of the tumor necrosis factor receptor
superfamily (TNFRSF). BCMA is found on the surfaces of plasma cells, is overexpressed
on malignant plasma cells and plays a key role in plasma cell proliferation and survival.
SLAMF7 is a member of the signaling lymphocytic activation molecule (SLAM) family
of transmembrane receptors that modulate the function of immune cells through immunoreceptor
tyrosine-based switch motifs (ITSMs) and intracellular adaptor proteins. SLAMF7 is
highly expressed on certain malignant plasma cells and is minimally expressed on healthy
immune cells. Targeting the two different TAAs highly expressed on malignant plasma
cells may improve coverage and protect against antigen escape and resistance as tumor
cells would need to lose both antigens.;
NCI Metathesaurus CUI : CL1407845;
Origin ID : C173967;
UMLS CUI : C5420488;
Semantic type(s)
- Cell [UMLS semantic type]
- concept_is_in_subset
- has_target
